시장보고서
상품코드
1619271

핵의학 시장 규모, 점유율, 성장 분석, 진단약, 치료제, 용도, 최종사용자, 지역별, 산업별 예측(2024-2031년)

Nuclear Medicine Market Size, Share, Growth Analysis, By Diagnostics (SPECT, PET), By Therapeutics (Alpha Emitters, Beta Emitters), By Application, By End User, By Region - Industry Forecast 2024-2031

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 157 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

핵의학 세계 시장 규모는 2022년 91억 달러로 평가되었고, 예측 기간(2024-2031년) 동안 11.8%의 연평균 복합 성장률(CAGR)로 2023년 101억 7,000만 달러에서 2031년 248억 3,000만 달러에 달할 전망입니다.

핵의학 시장은 강력한 제품 파이프라인과 첨단 진단 및 치료 옵션에 대한 접근성을 강화하기 위한 정부 지원 이니셔티브에 힘입어 성장하고 있습니다. 핵의학은 방사성의약품을 이용해 장기의 기능과 구조를 평가하는 여러 분야를 결합하는 분야로 갑상선암과 같은 질병의 조기 발견에 매우 중요합니다. 베탈루틴, 온브르타맙, 이트륨-90 마이크로스피어 등 주요 제품들이 현재 임상시험 중에 있으며, 코로나19 팬데믹으로 인한 어려움에도 불구하고 필수 서비스로 분류되는 원자로는 중요한 의약품을 공급하기 위해 가동을 계속하고 있습니다. 미국 암 협회는 전립선암의 높은 발병률과 최근 전이성 전립선암에 대한 플루빅토의 FDA 승인에서 알 수 있듯이 핵의학의 시급성을 강조하고 있으며, 이는 이 의료 분야의 중요성이 증가하고 있음을 강조하고 있습니다.

목차

서론

  • 조사 목적
  • 조사 범위
  • 정의

조사 방법

  • 정보 조달
  • 2차 데이터와 1차 데이터 방법
  • 시장 규모 예측
  • 시장 전제조건과 제한

주요 요약

  • 세계 시장 전망
  • 공급과 수요 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • Porter's Five Forces 분석과 영향
    • 경쟁 기업간 경쟁 관계
    • 대체품의 위협
    • 바이어의 교섭력
    • 신규 진출업체의 위협
    • 공급 기업의 교섭력

주요 시장 인사이트

  • 중요 성공 요인
  • 경쟁 정도
  • 주요 투자 기회
  • 시장 생태계
  • 시장의 매력 지수(2023년)
  • PESTEL 분석
  • 거시경제 지표
  • 밸류체인 분석
  • 가격 분석
  • 규제 상황
  • 특허 분석
  • 사례 연구

핵의학 시장 규모 : 진단별

  • 시장 개요
  • SPECT(단일 광자 방출 컴퓨터 단층촬영)
    • Technetium-99m
    • Thallium-201
    • Iodine-123
    • 기타
  • PET(양전자 방출 단층촬영)
    • Fluorine-18
    • Rubidium-82
    • 기타

핵의학 시장 규모 : 치료법별

  • 시장 개요
  • 알파 방사체
    • Radium-223
    • Actinium-225
  • 베타 방사체
    • Iodine-131
    • Yttrium-90
    • Lutetium-177
  • 근접 방사선 치료 동위 원소
    • 요오드 125
    • 팔라듐 103
    • 세슘 131

핵의학 시장 규모 : 용도별

  • 시장 개요
  • 종양학
    • 갑상선암
    • 골전이
    • 림프종
  • 심장병학
    • 심근관류 이미징
    • 심실 기능 영상
  • 신경학
    • 뇌 영상
    • 알츠하이머병
  • 기타
    • 소화기 내과
    • 신장학

핵의학 시장 규모 : 최종사용자별

  • 시장 개요
  • 병원
  • 진단센터
  • 연구기관

핵의학 시장 규모 : 지역별

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 스페인
    • 프랑스
    • 이탈리아
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 정보

  • 주요 5개사 비교
  • 주요 기업의 시장 포지셔닝(2023년)
  • 주요 시장 기업이 채택한 전략
  • 시장 최근 동향
  • 기업의 시장 점유율 분석(2023년)
  • 주요 기업 개요
    • 기업 개요
    • 제품 포트폴리오 분석
    • 부문별 점유율 분석
    • 매출 전년대비 비교(2021-2023년)

주요 기업 개요

  • GE Healthcare
  • Curium Pharma
  • Novartis
  • Cardinal Health
  • Lantheus Medical Imaging
  • Bracco Imaging S.P.A
  • Jubilant Life Sciences Ltd
  • Nordion(Canada), Inc.
  • Siemens Healthineers
  • Bayer AG
  • Eckert & Ziegler
  • Telix Pharmaceuticals
  • NorthStar Medical Radioisotopes, LLC
  • Shine Medical Technologies
  • Isotopia Molecular Imaging Ltd.
  • Institute of Isotopes Co., Ltd.
  • Mediso Ltd.
  • NTP Radioisotopes SOC Ltd.
  • ITM Isotopen Technologien Munchen AG
  • Radiopharm Theranostics

결론과 추천 사항

LSH 25.01.10

Global Nuclear Medicine Market size was valued at USD 9.1 billion in 2022 and is poised to grow from USD 10.17 billion in 2023 to USD 24.83 billion by 2031, growing at a CAGR of 11.8% during the forecast period (2024-2031).

The nuclear medicine market is experiencing growth, driven by a strong product pipeline and supportive government initiatives aimed at enhancing accessibility to advanced diagnostic and therapeutic options. This field combines multiple disciplines, utilizing radiopharmaceuticals to assess organ function and structure, crucial for early disease detection such as thyroid cancer. Key products, including betalutin, omburtamab, and yttrium-90 microspheres, are currently in clinical trials. Despite the challenges posed by the COVID-19 pandemic, nuclear reactors, classified as essential services, continued operations to provide critical medicines. The American Cancer Society highlights the urgency of nuclear medicine, as evidenced by the significant incidence of prostate cancer and the recent FDA approval of Pluvicto for metastatic cases, underscoring the growing importance of this medical specialty.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nuclear Medicine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nuclear Medicine Market Segmental Analysis

Global Nuclear Medicine Market is segmented by diagnostics, therapeutics, application, end user and region. Based on diagnostics, the market is segmented into SPECT (single photon emission computed tomography) (technetium-99m, thallium-201, iodine-123, others) and PET (positron emission tomography) (fluorine-18, rubidium-82, others). Based on therapeutics, the market is segmented into alpha emitters (radium-223, actinium-225), beta emitters (iodine-131, yttrium-90, lutetium-177) and brachytherapy isotopes (iodine-125, palladium-103, cesium-131). Based on application, the market is segmented into oncology (thyroid cancer, bone metastasis, lymphoma), cardiology (myocardial perfusion imaging, ventricular function imaging), neurology (brain imaging, alzheimer's disease) and others (gastroenterology, nephrology). Based on end user, the market is segmented into hospitals, diagnostic centers and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Nuclear Medicine Market

The Global Nuclear Medicine market is significantly driven by the increasing incidence and prevalence of cancer and cardiovascular disease (CVD). The World Health Organization reported that cancer was the leading cause of death in 2020, resulting in nearly 10 million fatalities, with projections indicating that 19.3 million new cancer cases will be diagnosed annually by 2025. Furthermore, in 2019, CVD was responsible for 17.9 million deaths, making up 32% of global mortality, and this figure is anticipated to climb to 23.3 million by 2030. The critical role of nuclear medicine in early diagnosis and treatment of these diseases is poised to propel market growth as demand for effective medical interventions rises.

Restraints in the Global Nuclear Medicine Market

The global nuclear medicine market faces several constraints, primarily due to the rising adoption of alternative diagnostic methods for various illnesses. While nuclear medicine techniques like PET scans are commonly used for cancer detection and cardiovascular imaging, technologies such as MRI and CT scans are increasingly favored, especially in developing countries. These alternatives are often more cost-effective, leading to greater utilization as they benefit from supportive reimbursement policies. Consequently, the shift towards these imaging modalities is likely to hinder the growth of the nuclear medicine market in the coming years, as healthcare providers opt for these less expensive diagnostic options.

Market Trends of the Global Nuclear Medicine Market

The global nuclear medicine market is witnessing a significant upward trend, driven by ongoing advancements in nuclear medicine therapies. Companies are increasingly focused on developing innovative therapies that showcase superior clinical efficacy compared to traditional treatment options, particularly in oncology and other high-burden diseases. This surge in demand is bolstered by regulatory endorsements, such as the US FDA's approval for Curium's Phase-III trial of lutetium Lu 177 PSMA I&T, a promising radiopharmaceutical targeting prostate cancer. Additionally, the emergence of new therapeutic agents by various market players is further stimulating growth, reflecting a robust pipeline geared toward addressing diverse medical conditions and enhancing patient care.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Driver & Opportunities
    • Restraints & Challenges
  • Porters Analysis & Impact
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2023
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Regulatory Landscape
  • Patent Analysis
  • Case Studies

Global Nuclear Medicine Market Size by Diagnostics & CAGR (2024-2031)

  • Market Overview
  • SPECT (Single Photon Emission Computed Tomography)
    • Technetium-99m
    • Thallium-201
    • Iodine-123
    • Others
  • PET (Positron Emission Tomography)
    • Fluorine-18
    • Rubidium-82
    • Others

Global Nuclear Medicine Market Size by Therapeutics & CAGR (2024-2031)

  • Market Overview
  • Alpha Emitters
    • Radium-223
    • Actinium-225
  • Beta Emitters
    • Iodine-131
    • Yttrium-90
    • Lutetium-177
  • Brachytherapy Isotopes
    • Iodine-125
    • Palladium-103
    • Cesium-131

Global Nuclear Medicine Market Size by Applications & CAGR (2024-2031)

  • Market Overview
  • Oncology
    • Thyroid Cancer
    • Bone Metastasis
    • Lymphoma
  • Cardiology
    • Myocardial Perfusion Imaging
    • Ventricular Function Imaging
  • Neurology
    • Brain Imaging
    • Alzheimer's Disease
  • Others
    • Gastroenterology
    • Nephrology

Global Nuclear Medicine Market Size by End User & CAGR (2024-2031)

  • Market Overview
  • Hospitals
  • Diagnostic Centers
  • Research Institutes

Global Nuclear Medicine Market Size & CAGR (2024-2031)

  • North America, (Diagnostics, Therapeutics, Applications, End User)
    • US
    • Canada
  • Europe, (Diagnostics, Therapeutics, Applications, End User)
    • UK
    • Germany
    • Spain
    • France
    • Italy
    • Rest of Europe
  • Asia-Pacific, (Diagnostics, Therapeutics, Applications, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America, (Diagnostics, Therapeutics, Applications, End User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa, (Diagnostics, Therapeutics, Applications, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2023
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

  • GE Healthcare
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Curium Pharma
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cardinal Health
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lantheus Medical Imaging
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bracco Imaging S.P.A
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Jubilant Life Sciences Ltd
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nordion (Canada), Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Siemens Healthineers
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eckert & Ziegler
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Telix Pharmaceuticals
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • NorthStar Medical Radioisotopes, LLC
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Shine Medical Technologies
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Isotopia Molecular Imaging Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Institute of Isotopes Co., Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mediso Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • NTP Radioisotopes SOC Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ITM Isotopen Technologien Munchen AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Radiopharm Theranostics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendation

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제